#### HALOZYME THERAPEUTICS INC

Form 4

March 28, 2007

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

C/O HALOZYME

SAN DIEGO, CA 92121

(City)

17

1. Name and Address of Reporting Person \* PATTON JOHN STUART

2. Issuer Name and Ticker or Trading Symbol

HALOZYME THERAPEUTICS INC [HTI]

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 03/28/2007

THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE

(Street)

(State)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

10% Owner Other (specify

Applicable Line)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

\_X\_\_ Director

Officer (give title

Issuer

below)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(A)

or

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) any (Month/Day/Year)

(Zip)

3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

5. Amount of

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Price Code V Amount (D) Common  $S^{(1)}$ 03/28/2007 600 D \$ 8.3 30,647 D Stock Common 03/28/2007  $S^{(1)}$ 100 D \$ 8.32 30,547 D Stock Common 03/28/2007  $S^{(1)}$ 1,716 D \$ 8.35 28,831 D Stock

Common  $S^{(1)}$ 03/28/2007 1,112 D D \$ 8.36 27,719 Stock

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	03/28/2007	S <u>(1)</u>	300	D	\$ 8.37 27,419	D
Common Stock	03/28/2007	S <u>(1)</u>	4,209	D	\$ 8.38 23,210	D
Common Stock	03/28/2007	S <u>(1)</u>	1,800	D	\$ 8.39 21,410	D
Common Stock	03/28/2007	S <u>(1)</u>	5,600	D	\$ 8.4 15,810	D
Common Stock	03/28/2007	S <u>(1)</u>	1,489	D	\$ 8.41 14,321	D
Common Stock	03/28/2007	S <u>(1)</u>	2,674	D	\$ 8.42 11,647	D
Common Stock	03/28/2007	S <u>(1)</u>	100	D	\$ 8.425 11,547	D
Common Stock	03/28/2007	S <u>(1)</u>	3,300	D	\$ 8.43 8,247	D
Common Stock	03/28/2007	S <u>(1)</u>	500	D	\$ 8.44 7,747	D
Common Stock	03/28/2007	S <u>(1)</u>	200	D	\$ 8.45 7,547	D
Common Stock	03/28/2007	S <u>(1)</u>	200	D	\$ 8.46 7,347	D
Common Stock	03/28/2007	S <u>(1)</u>	1,100	D	\$ 8.47 6,247	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orNumber	Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e	Securities	(Instr. 5)	Bene
	Derivative		•		Securities	8	(Instr. 3 and 4)		Own
	Security				Acquired		· ·		Follo
	•				(A) or				Repo
					Disposed				Trans
					of (D)				(Instr
					(Instr. 3,				Ì
					4, and 5)				
					,				
				Code V	(A) $(D)$		Title		

### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Date Expiration Exercisable Date

or Number of Shares

Amount

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

PATTON JOHN STUART C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CA 92121



# **Signatures**

/s/ John S. 03/28/2007 Patton

\*\*Signature of Date
Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3